RLMD
Relmada Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$3.58Close
$262.5MMarket cap
$2.20 – $7.8652-week range
Nov 12, 2026Next report
Highlights
Cautions
- Results soon Nov 12, 2026, in 10 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
54%
1wk
up 9.5%
price change
1mo
down 5.0%
price change
12-month return
up 54%
market up 11% ·
its own up 35%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.0×
price / book
Earnings yield
down 22.8%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
0%
return on equity
Free cash margin
—
-$45.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 143.0% over the year, from 30m to 73m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-10% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$60.8M | -$125.7M | -$161.2M | -$103.7M | -$83.9M | -$59.1M |
| Net income | -$59.5M | -$125.8M | -$157.0M | $0 | $0 | $0 |
| Earnings per share | — | -$7.16 | -$5.30 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$209.9M | -$91.9M | -$103.8M | -$51.7M | -$51.8M | -$45.8M |
| Cash | $2.5M | $44.4M | $5.4M | $4.1M | $3.9M | $3.5M |
| Long-term debt | $0 | — | — | — | — | — |
| Shareholders' equity | $105.6M | $208.3M | $140.4M | $85.4M | $35.5M | $86.5M |
| Shares outstanding | 16.33m | 27.74m | 30.10m | 30.10m | 30.17m | 73.33m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 19, 2026 | Annual ↗ | Dec 31, 2025 | 78d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 27, 2025 | Annual ↗ | Dec 31, 2024 | 86d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 19, 2024 | Annual ↗ | Dec 31, 2023 | 79d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 8, 2026 | Other events ↗ |
| Aug 6, 2026 | Results · Regulation FD ↗ |
| Jul 28, 2026 | Regulation FD ↗ |
| May 28, 2026 | Charter or bylaws · Shareholder vote ↗ |
| May 12, 2026 | Results · Regulation FD ↗ |
| Mar 20, 2026 | Results · Regulation FD ↗ |
| Mar 9, 2026 | Material agreement · Unregistered share sale · Regulation FD · Other events ↗ |
| Dec 15, 2025 | Director or officer change ↗ |
| Nov 13, 2025 | Results · Regulation FD ↗ |
| Nov 5, 2025 | Material agreement · Regulation FD ↗ |
| Nov 4, 2025 | Regulation FD · Other events ↗ |
| Sep 17, 2025 | Regulation FD ↗ |